Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

The Cancer Immunotherapy Drug Discovery Outsourcing Industry - Global Forecast 2026-2032 | AI and Strategic Partnerships Drive 10.33% CAGR, Unlocking a USD 3.21 Billion Opportunity by 2032

globenewswire.com

The Cancer Immunotherapy Drug Discovery Outsourcing Industry - Global Forecast 2026-2032 | AI and Strategic Partnerships Drive 10.33% CAGR, Unlocking a USD 3.21 Billion Opportunity by 2032 Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

This market research report examines the global cancer immunotherapy drug discovery outsourcing market, projected to grow from USD 1.77 billion in 2026 to USD 3.21 billion by 2032 at a CAGR of 10.33%. It analyzes the scientific, technological, regional, and strategic factors shaping demand for external oncology discovery capabilities, providing decision-makers with actionable intelligence for partner selection, market entry, and long-term investment planning.

Market Overview and Growth Drivers

Biopharmaceutical innovators increasingly rely on external partners for specialized oncology biology, translational immunology, bioinformatics, assay development, medicinal chemistry, biologics engineering, and clinical-enabling services. Demand is expanding as immuno-oncology pipelines move beyond checkpoint inhibitors into:

Outsourcing is particularly valuable in target validation, biomarker identification, immune profiling, preclinical pharmacology, toxicology, CMC-readiness planning, and multi-omics data integration. Growth is reinforced by the global cancer burden, precision oncology investment, and the need for improved patient stratification, response durability, and safety.

Transformative Market Shifts

The market is evolving from capacity-based procurement toward integrated discovery partnerships centered on translational outcomes. Sponsors increasingly favor providers that combine wet-lab immunology, computational biology, biomarker strategy, humanized models, high-content screening, and regulatory support.

Human-relevant platforms-including organoids, tumor-on-chip systems, single-cell sequencing, spatial biology, and immune-cell co-culture assays-are improving preclinical relevance. Regulatory expectations concerning reproducibility, traceability, and data integrity are also influencing vendor selection. These insights support risk mitigation by highlighting the quality, governance, and infrastructure capabilities required from outsourcing partners.

Artificial Intelligence in Immuno-Oncology Discovery

Artificial intelligence is advancing target prioritization, epitope prediction, lead optimization, biomarker discovery, antibody design, toxicity screening, and patient stratification. AI-enabled platforms integrate genomic, transcriptomic, proteomic, imaging, and clinical data to identify immune signatures associated with treatment response or resistance.

Effective application depends on validated datasets, transparent model governance, bias assessment, cybersecurity, and laboratory confirmation. Providers combining computational expertise with biologically relevant experimental platforms are positioned to deliver stronger translational evidence and accelerate candidate triage.

Regional and Country Insights

Coverage of G7, EU, BRICS, ASEAN, GCC, and NATO-aligned ecosystems enables organizations to compare regulatory maturity, talent availability, cost structures, data governance, and geopolitical exposure when developing market entry or vendor diversification strategies.

Strategic Priorities for Industry Leaders

Key Takeaways from This Report

Key Attributes

Key Topics Covered

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

7.1. Introduction

7.2. Clinical Development Services

7.3. Data Management And Biostatistics

7.3.1. Bioinformatics

7.3.2. Clinical Data Management

7.3.3. Statistical Analysis

7.4. Manufacturing Support

7.4.1. CMC Optimization

7.4.2. Process Development

7.5. Preclinical Services

7.5.1. Hit And Lead Discovery

7.5.2. Lead Optimization

7.5.3. Preclinical Safety Assessment

7.5.4. Target Identification

7.6. Regulatory Affairs Support

7.6.1. IND Filing Support

7.6.2. Regulatory Strategy Consulting

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Modality

8.1. Introduction

8.2. Cancer Vaccines

8.2.1. Dendritic Cell Vaccines

8.2.2. DNA Vaccines

8.2.3. Peptide Vaccines

8.2.4. RNA Vaccines

8.3. CAR T Cell Therapy

8.3.1. BCMA Targeted

8.3.2. CD19 Targeted

8.4. Checkpoint Inhibitors

8.4.1. CTLA-4 Inhibitors

8.4.2. PD-1 Inhibitors

8.4.3. PD-L1 Inhibitors

8.5. Cytokine Therapy

8.5.1. Colony Stimulating Factors

8.5.2. Interferons

8.5.3. Interleukins

8.6. Monoclonal Antibodies

8.6.1. Chimeric

8.6.2. Fully Human

8.6.3. Humanized

8.6.4. Murine

8.7. Oncolytic Virus Therapy

8.7.1. Adenovirus Based

8.7.2. HSV Based

8.7.3. Reovirus Based

9. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Workflow Stage

9.1. Introduction

9.2. Early Discovery

9.3. Lead Optimization

9.4. Preclinical Development

10. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Molecule Type

10.1. Introduction

10.2. Antibody-Based Molecules

10.3. Cell-Based Products

10.4. Gene-Modified Products

10.5. Peptide And Protein Therapeutics

10.6. Small Molecules

10.7. Nucleic Acid-Based Therapeutics

11. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Discovery Platform

11.1. Introduction

11.2. In Vitro Discovery Platforms

11.3. In Vivo Discovery Platforms

11.4. Ex Vivo Platforms

11.5. In Silico Platforms

12. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Outsourcing Model

12.1. Introduction

12.2. Full-Service Outsourcing

12.3. Functional Service Provider Outsourcing

12.4. Project-Based Outsourcing

12.5. Strategic Partnership Outsourcing

12.6. Dedicated Research Team Outsourcing

13. Cancer Immunotherapy Drug Discovery Outsourcing Market, by End User

13.1. Introduction

13.2. Academic Research Institutes

13.3. Biotechnology Companies

13.4. Government Research Institutes

13.5. Pharmaceutical Companies

14. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Area

14.1. Introduction

14.2. Solid Tumors

14.2.1. Lung Cancer

14.2.2. Breast Cancer

14.2.3. Colorectal Cancer

14.2.4. Melanoma

14.2.5. Prostate Cancer

14.2.6. Gastric Cancer

14.2.7. Liver Cancer

14.2.8. Ovarian Cancer

14.2.9. Pancreatic Cancer

14.2.10. Brain Cancer

14.3. Hematologic Malignancies

14.3.1. Lymphoma

14.3.2. Multiple Myeloma

14.3.3. Myelodysplastic Syndromes

14.3.4. Leukemia

15. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region

15.1. Introduction

15.2. Asia-Pacific

15.3. Europe

15.4. North America

15.5. Latin America

15.6. Africa

15.7. Middle East

16. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Group

16.1. Introduction

16.2. NATO

16.3. G7

16.4. European Union

16.5. BRICS

16.6. ASEAN

16.7. GCC

17. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Country

17.1. Introduction

17.2. United States

17.3. China

17.4. Germany

17.5. Japan

17.6. India

17.7. United Kingdom

17.8. France

17.9. Canada

17.10. Australia

17.11. Brazil

17.12. Italy

17.13. Mexico

17.14. South Korea

17.15. Russia

17.16. Spain

18. Competitive Landscape

18.1. Market Share Analysis, 2025

18.2. Market Concentration Analysis, 2025

18.2.1. Concentration Ratio (CR)

18.2.2. Herfindahl Hirschman Index (HHI)

18.3. Recent Developments & Impact Analysis, 2025

18.4. Product Portfolio Analysis, 2025

18.5. Benchmarking Analysis, 2025

19. Company Profiles

19.1. AbCellera Biologics Inc.

19.2. Absci Corporation

19.3. Adimab, LLC

19.4. Alloy Therapeutics, Inc.

19.5. Anthem Biosciences Limited

19.6. Aragen Life Sciences Limited

19.7. Champions Oncology, Inc.

19.8. Charles River Laboratories International, Inc.

19.9. ChemDiv, Inc.

19.10. Creative Biolabs, Inc.

19.11. Curia Global, Inc.

19.12. Domainex Ltd.

19.13. Enamine Ltd.

19.14. Eurofins Scientific SE

19.15. Evotec SE

19.16. GenScript Biotech Corporation

19.17. ImmunoPrecise Antibodies Ltd.

19.18. InSilico Medicine

19.19. JSR Corporation

19.20. NovAliX SAS

19.21. Pharmaron Beijing Co., Ltd.

19.22. ProMab Biotechnologies, Inc.

19.23. Reaction Biology Corporation

19.24. Sai Life Sciences Limited

19.25. Schrodinger, Inc.

19.26. Selvita S.A.

19.27. Shanghai Medicilon Inc.

19.28. Sygnature Discovery Limited

19.29. Syngene International Limited

19.30. Taconic Biosciences, Inc.

19.31. TCG Lifesciences Limited

19.32. The Jackson Laboratory

19.33. WuXi AppTec Co., Ltd.

19.34. WuXi Biologics (Cayman) Inc.

19.35. XtalPi Holdings Limited

20. Key Experts

List of Figures [27]

List of Tables [334]

For more information about this report visit https://www.researchandmarkets.com/r/loegaz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.